Kimera Labs Advances in Healthy Aging with $101 Million XPRIZE Healthspan Semifinalist Recognition

Kimera Labs' Journey Towards Extended Healthy Lifespans

In a remarkable milestone for the field of biotechnology, Kimera Labs, a pioneering company in therapeutic exosome technology, has been recognized as a semifinalist in the $101 million XPRIZE Healthspan competition. This prestigious recognition not only highlights the company's innovative approach to longevity but also reaffirms its commitment to enhancing human health.

Founded in 2012 by Duncan Ross, PhD, Kimera Labs specializes in the development of exosome-based therapeutics aimed at extending the healthy years of human life. The XPRIZE Healthspan initiative, launched in 2023, seeks to accelerate breakthroughs in science and technology that promise to improve human health and longevity. With over 660 applicants from 58 countries, Kimera was selected as one of the top 40 teams, distinguishing itself among a field of elite innovators focused on transforming aging and healthcare.

Kimera's selection as a semifinalist underscores its groundbreaking work in exosome biotechnology, specifically in developing innovations that target age-related diseases. The company operates out of a state-of-the-art, FDA-approved facility in Miramar, Florida, where it produces purified, cell-free exosome biologics using a single-donor perinatal MSC cell line. This stringent adherence to quality standards ensures that Kimera Labs sets a new benchmark for efficacy, safety, and purity in the field.

Central to the company's product line is XoGlo®, a therapeutic designed to address complications arising from conditions such as Acute Respiratory Distress Syndrome (ARDS). Approved for Phase I/IIa clinical trials, XoGlo highlights Kimera's commitment to regenerative treatments that support tissue regeneration, immune modulation, and promote healthy aging.

"We are honored to be recognized as a semifinalist in the XPRIZE Healthspan competition," expressed Duncan Ross, CEO of Kimera Labs. "This achievement reflects our team's decade-long dedication to scientific excellence and innovation, aiming to harness the potential of exosomes to enhance human health and longevity. Today's advancements suggest a potential lifespan extending to 100 or even 300 years, and the collaborations arising from the XPRIZE competition could help us reach that goal."

As part of the competition, Kimera Labs collaborates with Dr. Sheldon Jordan and the Regenesis Project to combine their hyper-isolated perinatal exosome technology with low-intensity focused ultrasound targeted at the brain. Preclinical results from this partnership, recently published in Nature Scientific Reports, demonstrate promising outcomes in alleviating age-related diseases, supporting tissue regeneration, and enhancing overall vitality.

Dr. Jordan commented on the partnership, stating, "The XPRIZE Healthspan competition presents a significant opportunity to advance global health. We are excited to join forces with Kimera Labs to accelerate the development of transformative innovations in the field of healthy aging."

The ultimate goal of the XPRIZE Healthspan competition is to award a grand prize to the team that devises the most promising and scalable solution by 2030, aimed at extending healthy lifespans and improving the quality of life worldwide. Kimera Labs is poised to play a pivotal role in this movement towards a healthier future, utilizing its expertise in exosome science to pioneer solutions that could redefine aging.

About Kimera Labs

Kimera Labs, founded in 2012 by Dr. Duncan Ross, is a leading clinical-stage exosome biotechnology company specializing in the development of exosome therapeutics. Leveraging its FDA-approved, single-donor perinatal MSC cell line and over a decade of scientific leadership, Kimera operates a 27,000-square-foot GMP-certified facility in Miramar, Florida. The company is dedicated to advancing the boundaries of exosome science with a strong commitment to innovation, precision, and improving human health throughout life.

About the Regenesis Project

The Regenesis Project, led by neurologist Dr. Sheldon Jordan, actively participates in numerous clinical research studies which provide patients access to the latest treatment techniques, including focused ultrasound, TMS, and light therapy. Ongoing studies address issues ranging from dementia and Parkinson's disease to chronic pain and traumatic brain injury.

About XPRIZE

XPRIZE is a global leader in designing and executing large-scale competitions aimed at solving humanity's grand challenges. For over 30 years, XPRIZE has democratized access to science-driven, scalable solutions that accelerate innovation toward a more equitable and abundant future.